FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2908141579> ?p ?o ?g. }

• W2908141579 endingPage "261" @default.
• W2908141579 startingPage "261" @default.
• W2908141579 abstract "Abstract Despite the remarkable pace of characterizing the genomics of pediatric acute leukemias, the integration of real-time sequencing results into clinical practice has lagged. With increased availability of molecularly-targeted therapies, the promise of matching genetic lesions in patients' leukemia cells to treatment has not yet been fully realized. We established the first pediatric leukemia clinical genomics consortium in the United States, known as the Leukemia Precision-based Therapy (LEAP) Consortium, which includes 13 major pediatric cancer institutions. We hypothesized that it is feasible to identify and match, in real-time, actionable alterations with a targeted therapy for pediatric patients with relapsed, refractory or high-risk leukemias or myelodysplastic syndrome (MDS). Using a combination of a DNA-based next-generation sequencing panel and RNA-based gene fusion testing, followed by data review by our multidisciplinary molecular tumor board, we are conducting a clinical trial to test this hypothesis. To date, we have enrolled and reviewed data from 143 patients stratified by disease status: Cohort 1, patients with relapsed or refractory leukemias (n=93), and Cohort 2, patients with de novo high-risk leukemias or MDS (n=50). A matched targeted therapy (MTT) recommendation has been made for 72% (n=103) of patients, tiered based on the level of evidence linking the mutation to potential activity of targeted therapy in the context of each patient's disease (Tier 1: 11%, Tier 2: 4%, Tier 3: 41%, Tier 4: 6%, Tier 5: 10%). Of the 44 patients in Cohort 1 with clinical follow-up data, 5 (11%) had alterations in therapy made based upon sequencing results and MTT recommendation. These include the use of the MEK inhibitor trametinib for RAS mutant acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL) (n=2), dasatinib for B-ALL and T-ALL with NUP214-ABL1 translocations (n=2) and ponatinib for B-ALL with an ABL1 T315I mutation (n=1). In addition, this genomic data refined diagnosis and supported additional germline assessment in a subset of patients. In parallel to the genomic sequencing, we are conducting high-throughput drug sensitivity (HTS) assays to study in vitro anti-leukemia effects of a panel of up to 120 targeted inhibitors in the context of leukemia-associated genetic alterations. Of the initial 106 accrued patients, 40 (38%) had adequate amounts of blood or bone marrow for in vitro drug testing. All samples were tested in the inhibitor panel assay, and 65% of the samples yielded interpretable results. Inhibitor screening data was compiled for all 12 patients with genetic alterations resulting in Tier 1, 2 or 3 MTT recommendations. This subset of patients had leukemias with two distinct molecular profiles: 1) oncogenic RAS signaling pathway mutations or 2) oncogenic tyrosine kinase alterations. Our molecular tumor board recommended trametinib for the first group of patients and tyrosine kinase inhibitors (TKIs), specific to the mutation, for the second group of patients. In vitro HTS data analysis demonstrated dose-response sensitivity of leukemia cells with RAS pathway mutations to trametinib, many of which had half-maximal inhibitory concentration (IC50) less than 50 nM. Similarly, leukemia cells from patients with FLT3, ABL1 or KIT mutations generally showed dose-responses to relevant TKIs with low IC50s. Overall, HTS data were concordant with MTT recommendations informed by the sequencing results. This first in the US multi-institutional prospective leukemia genomics trial brings state-of-the-art clinical genetic testing, assessment of prognostic biomarkers, selection of patients for germline testing, and targeted therapeutic treatment recommendations to children and young adults with high-risk, relapsed or refractory leukemias or MDS. Our collaboration provides a unique opportunity to perform sophisticated patient-specific in vitro drug testing assays to impact MTT discovery efforts, which we plan to validate in vivo using patient-derived xenograft models where feasible. We believe that a model like the LEAP Consortium has the potential to transform precision medicine approaches for children with high-risk leukemias and to inform future genomics-guided therapeutic trials and drug discovery efforts. Disclosures Tasian: Aleta Biopharmaceuticals: Membership on an entity's Board of Directors or advisory committees; Gilead Sciences: Research Funding; Incyte Corporation: Research Funding. Burke:JAZZ: Speakers Bureau; Shire: Speakers Bureau; AMGEN: Speakers Bureau. Tyner:AstraZeneca: Research Funding; Vivid Biosciences: Membership on an entity's Board of Directors or advisory committees; Takeda: Research Funding; Janssen: Research Funding; Array: Research Funding; Constellation: Research Funding; Gilead: Research Funding; Aptose: Research Funding; Incyte: Research Funding; Genentech: Research Funding." @default.
• W2908141579 created "2019-01-11" @default.
• W2908141579 creator A5007182073 @default.
• W2908141579 creator A5011985711 @default.
• W2908141579 creator A5014371302 @default.
• W2908141579 creator A5018962418 @default.
• W2908141579 creator A5019172032 @default.
• W2908141579 creator A5019291158 @default.
• W2908141579 creator A5022650568 @default.
• W2908141579 creator A5023214494 @default.
• W2908141579 creator A5033155482 @default.
• W2908141579 creator A5036283202 @default.
• W2908141579 creator A5037169725 @default.
• W2908141579 creator A5038841996 @default.
• W2908141579 creator A5042483676 @default.
• W2908141579 creator A5048748466 @default.
• W2908141579 creator A5053651370 @default.
• W2908141579 creator A5056053037 @default.
• W2908141579 creator A5058340446 @default.
• W2908141579 creator A5063929028 @default.
• W2908141579 creator A5066964026 @default.
• W2908141579 creator A5071293141 @default.
• W2908141579 creator A5075519499 @default.
• W2908141579 creator A5076948857 @default.
• W2908141579 creator A5079420293 @default.
• W2908141579 creator A5087508480 @default.
• W2908141579 creator A5087639347 @default.
• W2908141579 date "2018-11-29" @default.
• W2908141579 modified "2023-09-30" @default.
• W2908141579 title "Matched Targeted Therapy for Pediatric Patients with Relapsed, Refractory or High-Risk Leukemias: A Report from the LEAP Consortium" @default.
• W2908141579 doi "https://doi.org/10.1182/blood-2018-99-116948" @default.
• W2908141579 hasPublicationYear "2018" @default.
• W2908141579 type Work @default.
• W2908141579 sameAs 2908141579 @default.
• W2908141579 citedByCount "3" @default.
• W2908141579 countsByYear W29081415792020 @default.
• W2908141579 countsByYear W29081415792023 @default.
• W2908141579 crossrefType "journal-article" @default.
• W2908141579 hasAuthorship W2908141579A5007182073 @default.
• W2908141579 hasAuthorship W2908141579A5011985711 @default.
• W2908141579 hasAuthorship W2908141579A5014371302 @default.
• W2908141579 hasAuthorship W2908141579A5018962418 @default.
• W2908141579 hasAuthorship W2908141579A5019172032 @default.
• W2908141579 hasAuthorship W2908141579A5019291158 @default.
• W2908141579 hasAuthorship W2908141579A5022650568 @default.
• W2908141579 hasAuthorship W2908141579A5023214494 @default.
• W2908141579 hasAuthorship W2908141579A5033155482 @default.
• W2908141579 hasAuthorship W2908141579A5036283202 @default.
• W2908141579 hasAuthorship W2908141579A5037169725 @default.
• W2908141579 hasAuthorship W2908141579A5038841996 @default.
• W2908141579 hasAuthorship W2908141579A5042483676 @default.
• W2908141579 hasAuthorship W2908141579A5048748466 @default.
• W2908141579 hasAuthorship W2908141579A5053651370 @default.
• W2908141579 hasAuthorship W2908141579A5056053037 @default.
• W2908141579 hasAuthorship W2908141579A5058340446 @default.
• W2908141579 hasAuthorship W2908141579A5063929028 @default.
• W2908141579 hasAuthorship W2908141579A5066964026 @default.
• W2908141579 hasAuthorship W2908141579A5071293141 @default.
• W2908141579 hasAuthorship W2908141579A5075519499 @default.
• W2908141579 hasAuthorship W2908141579A5076948857 @default.
• W2908141579 hasAuthorship W2908141579A5079420293 @default.
• W2908141579 hasAuthorship W2908141579A5087508480 @default.
• W2908141579 hasAuthorship W2908141579A5087639347 @default.
• W2908141579 hasConcept C121608353 @default.
• W2908141579 hasConcept C126322002 @default.
• W2908141579 hasConcept C143998085 @default.
• W2908141579 hasConcept C151730666 @default.
• W2908141579 hasConcept C2778461978 @default.
• W2908141579 hasConcept C2779343474 @default.
• W2908141579 hasConcept C2781230642 @default.
• W2908141579 hasConcept C535046627 @default.
• W2908141579 hasConcept C71924100 @default.
• W2908141579 hasConcept C72563966 @default.
• W2908141579 hasConcept C86803240 @default.
• W2908141579 hasConceptScore W2908141579C121608353 @default.
• W2908141579 hasConceptScore W2908141579C126322002 @default.
• W2908141579 hasConceptScore W2908141579C143998085 @default.
• W2908141579 hasConceptScore W2908141579C151730666 @default.
• W2908141579 hasConceptScore W2908141579C2778461978 @default.
• W2908141579 hasConceptScore W2908141579C2779343474 @default.
• W2908141579 hasConceptScore W2908141579C2781230642 @default.
• W2908141579 hasConceptScore W2908141579C535046627 @default.
• W2908141579 hasConceptScore W2908141579C71924100 @default.
• W2908141579 hasConceptScore W2908141579C72563966 @default.
• W2908141579 hasConceptScore W2908141579C86803240 @default.
• W2908141579 hasIssue "Supplement 1" @default.
• W2908141579 hasLocation W29081415791 @default.
• W2908141579 hasOpenAccess W2908141579 @default.
• W2908141579 hasPrimaryLocation W29081415791 @default.
• W2908141579 hasRelatedWork W2008192462 @default.
• W2908141579 hasRelatedWork W2015206104 @default.
• W2908141579 hasRelatedWork W2315085516 @default.
• W2908141579 hasRelatedWork W2316407790 @default.
• W2908141579 hasRelatedWork W2465183438 @default.
• W2908141579 hasRelatedWork W2603773853 @default.
• W2908141579 hasRelatedWork W2964295425 @default.
• W2908141579 hasRelatedWork W4220940334 @default.
• W2908141579 hasRelatedWork W4226370902 @default.

• next